Boston Scientific has reportedly found a fix for its Lotus Edge heart valve after the company paused implantations of the device in October last year.
The Marlborough, Mass.-based company expects to submit a premarket application to the FDA in May, according to a Barclays report. The submission time would position Boston Scientific for approval by the end of the year, with a launch in early 2018.
Boston Scientific said it expects to see structural heart revenue of $300 million for 2017, up from $200 million this year, with contributions from its Watchman and Lotus/Lotus Edge devices.
The Marlborough, Mass.-based company expects to submit a premarket application to the FDA in May, according to a Barclays report. The submission time would position Boston Scientific for approval by the end of the year, with a launch in early 2018.
Boston Scientific said it expects to see structural heart revenue of $300 million for 2017, up from $200 million this year, with contributions from its Watchman and Lotus/Lotus Edge devices.
